Objective To evaluate whether magnesium sulphate (MgSO4) given to women at risk of very‐
preterm birth would be neuroprotective in preterm newborns and would prevent neonatal …

METHODS Overall, 573 women with fetuses of< 33 weeks' gestation whose birth was
planned within 24 hours were enrolled in 13 tertiary hospitals from 1997 to 2003, with 286 …

[Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm
newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective …

METHODS OF STUDY SELECTION: Randomized controlled trials comparing magnesium
sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for …

Prevention of neurologic disability associated with preterm birth is one of the major
challenges in current perinatal medicine. Magnesium sulfate (MgSO4), the focus of this …

ContextPrenatal magnesium sulfate may reduce the risk of cerebral palsy or death in very
preterm infants. ObjectiveTo determine the effectiveness of magnesium sulfate given for …

Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

There is an important unmet need to improve long term outcomes of encephalopathy for
preterm and term infants. Meta-analyses of large controlled trials suggest that maternal …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

In a French randomized trial, children at school-age demonstrated no evidence of harm from
fetal exposure to MgSO 4 before very preterm birth. Motor dysfunction/death, qualitative …